Renal Autologous Cell Therapy (REACT/ rilparencel)
Phase 3RecruitingInterest: 41/100
41
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Type 2 Diabetes Mellitus
Conditions
Type 2 Diabetes Mellitus, Chronic Kidney Diseases
Trial Timeline
Jan 5, 2022 → Dec 1, 2029
NCT ID
NCT05099770About Renal Autologous Cell Therapy (REACT/ rilparencel)
Renal Autologous Cell Therapy (REACT/ rilparencel) is a phase 3 stage product being developed by ProKidney for Type 2 Diabetes Mellitus. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05099770. Target conditions include Type 2 Diabetes Mellitus, Chronic Kidney Diseases.
What happened to similar drugs?
20 of 20 similar drugs in Type 2 Diabetes Mellitus were approved
Approved (20) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
17
Activity
15
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05099770 | Phase 3 | Recruiting |
Competing Products
20 competing products in Type 2 Diabetes Mellitus